Cissus for Weight and Metabolic Outcomes: The Trials
This is the strange part of the Cissus file. The plant's traditional claim is fracture healing, where the evidence is old, weak and positive. The plant's commercial claim is weight loss — and there the evidence is modern, randomised, placebo-controlled, and compromised in a different way. There really are double-blind trials reporting weight, body-fat, lipid and glucose improvements. They are also small, short, clustered around a handful of investigators and one proprietary extract, and — the point that matters most — several of them administered a multi-ingredient product, which means a positive result cannot be credited to Cissus quadrangularis without checking what was in the capsule.
That last problem is not a technicality. It is the difference between "this plant reduces body fat" and "a formula containing this plant plus another plant reduces body fat", and the supplement market prints the first while citing the second.
Table of Contents
- What Is Claimed
- The Trials, Read as Designs
- What Was Actually Administered
- Investigator Clustering and Sponsorship
- Proposed Mechanisms
- The Cortisol-Blocker Story
- Glucose and Lipids: Benefit and Hazard in One Property
- Eight Weeks and What It Cannot Tell You
- What a Trial That Settled This Would Need
- Against Interventions That Do Have Evidence
- Evidence Ledger
- Numbers This Page Refuses to Give
- Key Research Papers
- Connections
- Featured Videos
What Is Claimed
The marketing bundle usually contains five separate assertions:
- Body weight and body fat fall on a Cissus extract, with or without diet change.
- Metabolic-syndrome markers improve — total and low-density lipoprotein (LDL) cholesterol, triglycerides, fasting glucose.
- Appetite is reduced, usually attributed to serotonergic or hormonal effects.
- Fat absorption is reduced by pancreatic lipase inhibition.
- Cortisol is "blocked", preventing stress-related abdominal fat gain.
Claims 1 and 2 have randomised human trials behind them, and this page takes them seriously. Claims 3 and 4 rest on enzyme assays and animal work. Claim 5 has essentially nothing and is discussed separately because it is the most confidently asserted of the five.
The Trials, Read as Designs
Evidence tier: randomised, placebo-controlled, small, short, clustered, a proprietary extract, and in several cases multi-ingredient.
The core body of work comes from a group publishing out of Cameroon in Lipids in Health and Disease in the mid-to-late 2000s, associated with J. E. Oben and colleagues, using proprietary standardised Cissus extract material.
- Oben and colleagues, 2006 — The use of a Cissus quadrangularis formulation in the management of weight loss and metabolic syndrome. Randomised, double-blind and placebo-controlled in 123 overweight and obese adults over eight weeks, with reported reductions in body weight and central obesity and improvements in lipid and glucose measures. Note the word "formulation" in the title. The abstract does not list what the capsule contained, so this page does not assume it was a single ingredient.
- Oben and colleagues, 2007 — a study contrasting a proprietary single-plant Cissus extract (300 mg a day) with a proprietary multi-ingredient formulation containing it (1,028 mg a day) in obesity and obesity-induced oxidative stress. The double-blind, placebo-controlled part enrolled 168 overweight and obese people, of whom 153 completed it. Both the single extract and the formula were reported to bring significant reductions in weight, body fat, total and LDL cholesterol, triglycerides and fasting blood glucose over the study period. This is one of three designs in the file with a single-plant arm, alongside the 2008 and 2019 trials below.
- Oben and colleagues, 2008 — The use of a Cissus quadrangularis / Irvingia gabonensis combination in the management of weight loss: a double-blind placebo-controlled study. Three arms of 24 people each (72 in all): Cissus alone, Cissus plus Irvingia gabonensis, and placebo, over ten weeks. The Cissus-only arm showed significant reductions on all six measures (body weight, body fat, waist size, total cholesterol, LDL cholesterol and fasting blood glucose) compared with placebo, and the combination arm was reported as the largest effect. The combination is the headline result, and Irvingia gabonensis is a separate plant with its own weight-loss literature from the same research group. A larger effect in a two-plant arm is evidence about two plants.
- Nash, Oben and colleagues, 2019 — the single-plant extract alone. An 8-week double-blind, placebo-controlled pilot trial by the same Cameroon group, in 67 overweight people asked to keep their normal diet and exercise: 35 took 300 mg a day of the single-plant extract and 32 took 300 mg of corn starch. Body fat was measured two ways. On Cissus it fell 8.9% by bioelectrical impedance and 12.8% by DEXA (dual-energy X-ray absorptiometry) scan; on placebo it fell 1.05% by impedance and did not change on DEXA. Compared with placebo, the Cissus group also had significant decreases in waist and hip circumference, systolic and diastolic blood pressure, total cholesterol, triglycerides, fasting blood glucose and leptin, and increases in high-density lipoprotein (HDL) cholesterol and adiponectin. The paper's conflict-of-interest statement says the study was funded by the University of Yaoundé 1, where two of its authors work.
- Smaller pilot and open-label studies using various extracts, sometimes alongside dietary advice, reporting modest weight and lipid changes. Several lacked blinding. These add volume rather than strength.
- Sawangjit and colleagues, 2017 — systematic review and meta-analysis of randomised trials of Cissus quadrangularis in clinical use, in Phytotherapy Research. It included 9 trials with 1,108 patients across indications. For weight it could pool only combination products, which outperformed placebo: body weight −5.19 kg (95% confidence interval −8.82 to −1.55), LDL cholesterol −14.43 mg/dl, triglycerides −37.50 mg/dl, total cholesterol −50.50 mg/dl and fasting blood sugar −10.39 mg/dl. By GRADE (Grading of Recommendations Assessment, Development and Evaluation) it rated the evidence from low quality (bone fractures) to high quality (hemorrhoids, body-weight reduction), and it concluded that high-quality studies are still needed. This is the appropriate reference for anyone who wants one citation rather than five.
What Was Actually Administered
This is the decisive methodological point on the page, and it generalises well beyond Cissus.
When a trial administers a formula and reports a benefit, the benefit belongs to the formula. Crediting it to one named constituent requires either a single-ingredient arm, or a design that isolates the component. In the Cissus weight-loss literature:
- The most cited positive result involves a two-plant combination. The 2008 study's strongest arm paired Cissus with Irvingia gabonensis — African mango — which the same group had separately published on as an anti-obesity agent in its own right. Where the combination outperforms Cissus alone, the honest reading is that some or all of the extra effect is attributable to the second plant, not that Cissus was "potentiated".
- Titles containing the word "formulation" are a flag, not a detail. A product name is not an ingredient list. Before this or any page credits a plant with a trial result, the composition of the tested material has to be established from the methods section.
- A formula whose stated purpose is amplification undermines single-component attribution twice over — once because the ingredients are confounded, and again because the design concedes that the single ingredient was thought insufficient.
- Shelf products compound the problem. Consumer Cissus products routinely add green tea extract, caffeine, chromium, garcinia or Irvingia. A shopper who reads "clinically studied" on such a label is being pointed at trials of a different mixture than the one in their hand.
What this page therefore claims: that randomised trials of Cissus-containing materials have reported weight and metabolic improvements; that three designs (2007, 2008 and 2019) included a single-plant arm, each reporting significant reductions with it, all from the same research programme; that the largest effects, and the only pooled weight result, come from combination products; and that the composition of the tested material is found in the methods rather than the abstract.
Investigator Clustering and Sponsorship
Reporting funding and authorship relationships is not an accusation; it is part of describing the evidence, and it is disclosed in the papers themselves.
- The positive weight-loss literature is concentrated. A large share of it shares investigators, a country of conduct, a journal, and a proprietary source of test material. Independent replication means a different group, different funding and a different site reaching the same result — and that has not happened at scale for Cissus.
- One independent group has reported. Researchers at Mahidol University in Thailand, who declared no competing interests, reported in 2021 that obese people taking Cissus had smaller waists at 4 and 8 weeks and smaller hips at 8 weeks. The abstract compares these with the participants' own starting values, not with a placebo group. In human fat cells grown in the laboratory (not in people), the extract raised uncoupling protein 1 (UCP1), a gene marker of fat "browning".
- The test material was proprietary. Trials of a single trade-named extract are normal in supplement research and not disqualifying. They do mean that the finding attaches to that specific extract rather than to the species. The one funding statement read for this page, in the 2019 trial, says that study was funded by the University of Yaoundé 1, where two of its authors work.
- The narrative review. The widely cited narrative review of Cissus efficacy and safety by Stohs and Ray in Phytotherapy Research (2013) compiles the animal, human and laboratory studies. It concluded that several human studies support Cissus extracts in weight management, and that better standardisation of extracts and more well-controlled human studies are required.
- Publication of null results is the missing control. A supplement with commercial value and a small number of active investigators is exactly the situation in which a negative study is least likely to be written up. The absence of published negative trials is not evidence of an absence of negative results.
Proposed Mechanisms
Four mechanisms are offered. All are hypotheses about why an effect might exist rather than evidence that it does.
- Pancreatic lipase inhibition. Extracts inhibit lipase in vitro. This is the mechanism of orlistat, a drug whose real-world signature is unmistakable gastrointestinal fat loss. Cissus trials do not report that signature, which argues that whatever lipase inhibition occurs in a test tube is not occurring meaningfully in the human gut.
- Alpha-amylase and alpha-glucosidase inhibition. Also demonstrated in enzyme assays. The same objection applies: an inhibitory concentration in a cuvette is not a dose, and there is no adequate human pharmacokinetic study of the constituents to bridge the gap.
- Appetite and satiety effects. Proposed from animal work and from serotonergic speculation. Human appetite endpoints — validated satiety scales, ad libitum intake measurement — have not been properly applied.
- Effects on adipocyte differentiation. Cell work reports changes in adipogenesis markers. Note that the most-cited adipogenesis paper from this research programme concerns Irvingia gabonensis seed extract, not Cissus — a clean example of why constituent attribution has to be checked at every citation.
The Cortisol-Blocker Story
Cissus is sold across the fitness market as a "cortisol blocker" that prevents stress-driven abdominal fat gain. This deserves its own section because it is asserted with more confidence than anything else on the label and supported by less.
What exists: the plant contains phytosterols and, by the industry's own standardisation, a fraction marketed as "ketosterones", and 3-ketosteroids are structurally in the same broad chemical territory as steroid hormones. What does not exist: any adequate human study showing that oral Cissus lowers cortisol, and any study linking such a change to fat distribution. Structural resemblance is not pharmacology.
Two further problems sit underneath the claim. First, the ketosterone assay is not standardised between laboratories, so the marketed fraction is not a defined quantity. Second, "blocking cortisol" is not obviously desirable even if it were achievable — cortisol is required for glucose regulation, blood pressure and the response to physical stress, and an agent that genuinely suppressed it would carry the safety profile of a corticosteroid antagonist, not of a fat burner. A mechanism that would be dangerous if true, and is asserted without evidence, is worth naming as marketing rather than pharmacology.
Glucose and Lipids: Benefit and Hazard in One Property
Several trials and animal studies report lower fasting glucose with Cissus. Taken as a benefit claim this is modest and unconfirmed. Taken as a safety observation it is the most practically important finding on this page — and it is the same property described twice.
If the glucose-lowering effect is real, it is additive with the drugs people already take for that purpose: metformin, sulfonylureas such as glipizide, glyburide and glimepiride, meglitinides, and insulin. Someone whose medication was titrated before they started the supplement can drift into more frequent hypoglycaemia, and the symptoms — shakiness, sweating, confusion — are easily misread as a side effect of the herb rather than an interaction with the prescription. An added glucose-lowering effect on top of these medicines raises the risk of low blood sugar (hypoglycaemia), whose signs include shakiness, sweating and confusion. This is expanded in Cissus: Dose, Formulations and Safety.
The reported lipid changes carry a milder version of the same logic for someone on a statin or an antihypertensive: no interaction is documented, but an unmeasured variable has been added to a titrated regimen. See Lipid Panel and Hemoglobin A1C.
Eight Weeks and What It Cannot Tell You
The trials ran roughly eight to ten weeks. Three things follow, and they are not minor.
- Nothing about weight maintenance. Almost any intervention produces weight loss over eight weeks; the entire difficulty of obesity treatment is the twelve to twenty-four month horizon, where most losses are regained. A short trial cannot address the actual clinical question. See Obesity.
- Nothing about safety over the period of real use. People take supplements for years. Eight weeks cannot detect a slowly accumulating harm, and with a plant carrying meaningful oxalate that is not an abstract concern — see Kidney Stones.
- Nothing about uncommon adverse events. A hundred participants split across arms cannot detect a harm occurring in one user in a few hundred.
What a Trial That Settled This Would Need
Naming the study that would resolve the question is more useful than hedging, and obesity pharmacotherapy has a mature, well-specified trial methodology to borrow from.
- A single-ingredient, assayed intervention with a documented certificate of analysis, so the trial tests the plant and not a mixture.
- Randomised, double-blind, placebo-controlled, with a matched placebo and allocation concealment.
- Twelve months minimum, which is the standard duration for a weight-loss agent, with a maintenance phase.
- Percentage body-weight change as the primary endpoint, plus the proportion of participants achieving five and ten percent loss — the thresholds regulators and clinicians use.
- Body composition by DXA or equivalent, not bioimpedance, so a fat-versus-lean claim can be made honestly.
- Standardised background diet and activity, or at minimum measured and reported, since unmeasured lifestyle change is the commonest confounder in supplement trials.
- Prespecified metabolic secondary endpoints: fasting glucose, hemoglobin A1c (HbA1c), a full lipid panel, blood pressure, waist circumference.
- Adequate power for a modest effect, meaning several hundred participants across multiple independent sites.
- Pre-registration, intention-to-treat analysis and an independent statistician.
None of this is beyond a botanical. It is how orlistat, and later the glucagon-like peptide-1 (GLP-1) agonists, were assessed. Twenty years after the first positive Cissus trial, no study of this shape has been published.
Against Interventions That Do Have Evidence
The point of naming comparators is to show that the question is answerable, not to sell an alternative.
- Dietary pattern change with adequate protein has the largest and longest human evidence base for weight and metabolic markers, and it is free.
- Resistance and aerobic training alter body composition and insulin sensitivity with trial evidence measured in decades, not weeks. See Insulin Resistance.
- Prescription pharmacotherapy, where indicated, has year-long randomised trials with percentage-weight-loss endpoints. Whatever one thinks of it, that is the evidentiary bar a supplement claim is implicitly comparing itself to.
- Metabolic-syndrome management as a whole — blood pressure, lipids, glucose, waist circumference — is a well-defined clinical target with established interventions. See Metabolic Syndrome.
Evidence Ledger
- Best supported: that randomised placebo-controlled trials of Cissus-containing materials have reported short-term weight, body-fat, lipid and fasting-glucose improvements. Tier: modern randomised human evidence, small, short, clustered, and in several cases multi-ingredient.
- Materially weaker than it looks: attribution of those results to Cissus quadrangularis alone. Tier: partly confounded — three designs (2007, 2008 and 2019) included a single-plant arm and each reported significant reductions with it, but the most-cited headline result is the two-plant arm, and all three come from one research programme.
- Mechanistic, not clinical: lipase, amylase and glucosidase inhibition. Tier: in vitro, with no human pharmacokinetics to bridge the gap.
- Asserted without evidence: cortisol blocking. Tier: marketing — and a mechanism that would carry corticosteroid-antagonist risks if it were real.
- Outside view: a 2020 meta-analysis of 54 placebo-controlled trials of herbal medicines for weight loss listed Cissus quadrangularis among the herbs, each tested in three or fewer trials, for which statistically and clinically significant weight loss compared with placebo had been reported (clinically significant meaning a difference of at least 2.5 kg). The authors wrote that these findings "should be interpreted cautiously because of the small number of studies, generally poor methodological quality, and poor reporting of the herbal medicine interventions", and concluded: "There is currently insufficient evidence to recommend any of the herbal medicines for weight loss included in the present review."
- Absent: anything about weight maintenance beyond ten weeks, and anything about safety over years of use.
- The most robust finding on this page is a safety observation, not a benefit: the reported glucose-lowering effect, which matters most to people taking diabetes medication.
Numbers This Page Refuses to Give
- A kilograms-lost or percentage-body-fat figure. Quoting a single small trial's effect size as an expected result would misrepresent both its precision and its generalisability, and several of the figures in circulation come from the multi-ingredient arms. The figures quoted above are what each study reported for its own participants, not an expected result.
- A recommended dose. The trials used a few hundred milligrams a day of a specific proprietary extract, split before meals. That is a description of what was administered in one programme, not a dose established for anyone, and shelf products frequently exceed it because a bigger number sells.
- A ketosterone percentage. The assay is not standardised across laboratories, so the printed figure is not comparable between products.
- A cortisol effect size. There is nothing adequate to quote.
- Participant counts and durations are not refused: secondary sources disagree on them, but the primary abstracts give them exactly. 2006: 123 overweight or obese people, 8 weeks. 2007: 168 enrolled and 153 completed, 300 mg a day of the single extract or 1,028 mg a day of the formula. 2008: 72 people in three groups of 24, 10 weeks. 2019: 67 people, 8 weeks.
Key Research Papers
Entries ending in a PubMed PMID link to the verified record of that paper; entries ending in “Search PubMed” are topic searches, not single papers. Citations involving a second plant or a formulation are labelled as such at the citation.
- Systematic review and meta-analysis — the appropriate single citation. Sawangjit R, Puttarak P, Saokaew S, Chaiyakunapruk N. Efficacy and safety of Cissus quadrangularis L. in clinical use: a systematic review and meta-analysis of randomised controlled trials. Phytotherapy Research, 2017;31(4):555-567. PubMed PMID: 28165166
- The 2006 trial — note "formulation" in the title; the abstract does not give the composition of the tested material. Oben J, Kuate D, Agbor G, Momo C, Talla X. The use of a Cissus quadrangularis formulation in the management of weight loss and metabolic syndrome. Lipids in Health and Disease, 2006;5:24. PubMed PMID: 16948861
- Single plant versus formulation, side by side — one of three designs with a single-plant arm. Oben JE, Enyegue DM, Fomekong GI, Soukontoua YB, Agbor GA. The effect of Cissus quadrangularis (CQR-300) and a Cissus formulation (CORE) on obesity and obesity-induced oxidative stress. Lipids in Health and Disease, 2007;6:4. PubMed PMID: 17274828
- Two-plant combination — the headline arm is not Cissus alone. Oben JE, Ngondi JL, Momo CN, Agbor GA, Sobgui CS. The use of a Cissus quadrangularis/Irvingia gabonensis combination in the management of weight loss: a double-blind placebo-controlled study. Lipids in Health and Disease, 2008;7:12. PubMed PMID: 18377661
- The single-plant extract alone against placebo. Nash R, Azantsa B, Kuate D, Singh H, Oben J. The use of a stem and leaf aqueous extract of Cissus quadrangularis (CQR-300) to reduce body fat and other components of metabolic syndrome in overweight participants. Journal of Alternative and Complementary Medicine, 2019;25(1):98-106. PubMed PMID: 29912570
- Different plant — cited to show where part of the combination effect may live. This is African mango, not Cissus, studied in mouse fat cells in the laboratory. Oben JE, Ngondi JL, Blum K. Inhibition of Irvingia gabonensis seed extract (OB131) on adipogenesis as mediated via down regulation of the PPARgamma and leptin genes and up-regulation of the adiponectin gene. Lipids in Health and Disease, 2008;7:44. PubMed PMID: 19014517
- Narrative review. Stohs SJ, Ray SD. A review and evaluation of the efficacy and safety of Cissus quadrangularis extracts. Phytotherapy Research, 2013;27(8):1107-14. PubMed PMID: 22976133
- Independent group, waist and hip compared with baseline; fat-cell result in the laboratory. Chatree S, Sitticharoon C, Maikaew P, Pongwattanapakin K, Keadkraichaiwat I, Churintaraphan M, Sripong C, Sririwichitchai R, Tapechum S. Cissus Quadrangularis enhances UCP1 mRNA, indicative of white adipocyte browning and decreases central obesity in humans in a randomized trial. Scientific Reports, 2021;11(1):2008. PubMed PMID: 33479386
- Herbal weight-loss meta-analysis. Maunder A, Bessell E, Lauche R, Adams J, Sainsbury A, Fuller NR. Effectiveness of herbal medicines for weight loss: a systematic review and meta-analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2020;22(6):891-903. PubMed PMID: 31984610
- Enzyme-inhibition mechanism — in vitro only. Reports of pancreatic lipase, alpha-amylase and alpha-glucosidase inhibition by Cissus quadrangularis extracts. Confirm journals and years from the records; these are assays, not doses. — Search PubMed
- Antihyperglycaemic and antihyperlipidaemic animal work. Rodent studies reporting lower glucose and improved lipid profiles with Cissus quadrangularis extracts — the preclinical basis of the safety point in this page rather than of a treatment claim. — Search PubMed
- Safety assessment of a standardised extract. Subchronic toxicity and genotoxicity evaluation of a standardised Cissus quadrangularis extract, published in the toxicology literature around 2011. Metadata should be confirmed from the record. — Search PubMed
- How weight-loss agents are actually assessed. Regulatory-standard endpoints in obesity pharmacotherapy trials — twelve-month duration, percentage weight change, five and ten percent responder thresholds. The bar a supplement claim is implicitly measuring itself against. — Search PubMed
- Why short trials mislead. Long-term weight-regain literature after successful short-term loss. — Search PubMed
PubMed Topic Searches
- Cissus quadrangularis, obesity, randomised trials
- Cissus quadrangularis and metabolic syndrome
- Cissus quadrangularis and blood glucose
- Cissus quadrangularis and cortisol — see how little returns.
- Irvingia gabonensis and weight loss — the other plant in the combination.
External Resources
Connections
- All Herbs
- Cissus quadrangularis — botany, names, constituents, full cautions.
- Cissus for Bone and Fracture Healing — the traditional claim, and a very different evidence problem.
- Cissus for Joint and Tendon Pain — the other fitness-market claim, resting on one pilot study.
- Cissus: Dose, Formulations and Safety — the diabetes-medication interaction in detail.
- Obesity — why a ten-week trial cannot answer the clinical question.
- Metabolic Syndrome — the cluster these trials measured.
- Insulin Resistance — the mechanism underneath the glucose findings.
- Diabetes — where the reported glucose effect becomes a safety matter.
- Hemoglobin A1C — the endpoint a serious metabolic trial would report.
- Lipid Panel — the lipid changes these trials reported.
- Kidney Stones — the oxalate concern over long-term use.
- Ashwagandha — the other herb sold on a cortisol story, with more human data behind it.
- Resveratrol — the grape-family literature that keeps getting borrowed for this vine.